article thumbnail

Relative importance of pharmaceuticals on health outcomes: 1990-2015

Healthcare ECONOMIST

Is it new surgical techniques, better diagnostics, improved medical devices, or new pharmaceuticals? Based on physicians responses, across all 8 diseases , pharmaceuticals had the largest impact on health. Across all 8 diseases 56% of the relative value came from pharmaceuticals. Clearly public health initiatives (e.g.,

article thumbnail

Vertical Integration in the Pharmaceutical Market

Healthcare ECONOMIST

better accounting for medical costs offsets). On the one hand, integration may beneficial to consumers. It could: (i) improve operational efficiencies, and (ii) better align PBM incentives with those of the health plan (e.g.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Many Hospitals Receiving Discounted Drugs May Not Offer Patients Pharmaceutical Assistance

Bill Of Health

Section 340B of the Public Health Service Act requires that pharmaceutical manufacturers give discounts on specified outpatient drugs to certain covered entities who typically serve low-income or otherwise underserved patients, including hospitals and clinics. billion and accounting for a third of U.S. billion, reaching $6.3

article thumbnail

U.S. Hospitals Will Lose $323 Billion in 2020 – Before Accounting for Growing COVID Cases

Health Populi

To the pharmaceutical industry, it’s the annual revenue generated from 323 blockbuster drugs, as “blockbusters” are defined as products yielding $1 bn in sales a year. Hospitals Will Lose $323 Billion in 2020 – Before Accounting for Growing COVID Cases appeared first on HealthPopuli.com. The post U.S.

article thumbnail

Insights Management: A New Paradigm for Cancer Treatment

HIT Consultant

Lance Hill, CEO of Within3 The cancer market for the pharma industry accounts for about a third of their product pipeline. In this nuanced landscape, pharmaceutical companies play a vital role in driving advancements in cancer care. A recent study estimated the cost of developing a new drug at $2.6

article thumbnail

JAPAC Drug Development: Navigating Safety & Regulatory Requirements

HIT Consultant

In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. They are also in communication with the sponsor, who is the MAH of the active pharmaceutical ingredient. In comparison to Japan, China has fewer distinctions.

article thumbnail

How AI and machine learning can help predict SDOH needs

Healthcare It News

Care managers and social workers, working within accountable care organizations, and physician provider networks now incorporate a short series of SDOH interview questions with patients identified as high-risk for poor healthcare outcomes or unnecessary future healthcare expenditures.